Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Mass Balance Study of Eliapixant in Healthy Men
NCT04487431Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of eliapixant in overactive bladder (OAB), endometriosis, chronic cough and 1 more (2 arms), sponsored by Bayer. Primary endpoints: Area Under the Curve of BAY1817080 in plasma, Maximum observed concentration of BAY1817080 in plasma and 2 more. Started Aug 2020; status: completed.
02
Drugs
eliapixant
03
Conditions
overactive bladder (OAB)endometriosischronic coughdiabetic neuropathy
Beyond the preview
Go deeper on NCT04487431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04487431.